Solventum Earnings Reports

In Q2 2025, Solventum achieved higher sales and maintained profitability despite margin pressures from higher operating costs and lower gross margins. The company saw positive organic sales growth in all segments, particularly MedSurg and Health Information Systems, and raised its full-year revenue and earnings guidance.

Solventum achieved 4.3% organic sales growth in Q1 2025, driven by strong performance in MedSurg and Health Information Systems. Despite the increase in revenue, net income and operating income fell sharply year-over-year due to higher costs and margin pressures. Free cash flow turned negative, reflecting investment and operating dynamics post-spin-off.

Solventum delivered a solid quarter with total sales reaching $2.074 billion, marking a 1.9% increase year-over-year. GAAP diluted EPS stood at $0.17, while adjusted EPS reached $1.41. The company generated $219 million in operating cash flow and achieved $92 million in free cash flow. Organic sales growth was led by MedSurg and Dental Solutions segments.

Solventum reported a 0.4% increase in sales to $2.082 billion for Q3 2024, with organic sales increasing by 0.3%. GAAP EPS was $0.70, and adjusted EPS was $1.64. The company generated $169 million in cash from operations and $76 million in free cash flow. Solventum raised its full-year 2024 organic sales growth, adjusted EPS, and free cash flow guidance.

Solventum reported its Q2 2024 financial results, highlighting a slight increase in reported sales and organic sales growth. The company's GAAP EPS was $0.51, while adjusted EPS reached $1.56. Solventum generated $355 million in cash from operations and $297 million in free cash flow. The company also raised its full-year 2024 organic sales growth and adjusted EPS guidance.

Solventum reported its first quarter 2024 financial results, marking its first quarter as an independent company after the spin-off from 3M on April 1, 2024. Sales increased by 0.2% to $2.016 billion, with organic sales up by 0.9%. The company reported GAAP EPS of $1.37 and adjusted EPS of $2.08. Solventum generated $442 million in cash from operations and $340 million in free cash flow. The company reaffirms its full-year 2024 guidance.